PURPOSE: This study was conducted to examine the bone and body composition effects of S-4, an aryl-propionamide derived Selective Androgen Receptor Modulator (SARM) in an ovariectomy induced model of accelerated bone loss. METHODS: One hundred twenty female Sprague-Dawley rats aged to twenty-three weeks were randomly assigned to twelve treatment groups. Drug treatment was initiated immediately following ovariectomy and continued for one hundred twenty days. Whole body bone mineral density (BMD), body composition, and lumbar vertebrae BMD were measured by dual energy x-ray absorptiometry. More stringent regional pQCT and biomechanical strength testing was performed on excised femurs. RESULTS: We found that S-4 treatment maintained whole body and trabecular BMD, cortical content, and increased bone strength while decreasing body fat in these animals. CONCLUSIONS: The data presented herein show the protective skeletal effects of S-4. Our previous reports have shown the tissue selectivity and muscle anabolic activity of S-4. Together these data suggest that S-4 could reduce the incidence of fracture via two different mechanisms (i.e., via direct effects in bone and reducing the incidence of falls through increased muscle strength). This approach to fracture reduction would be advantageous over current therapies in these patients which are primarily antiresorptive in nature.
PURPOSE: This study was conducted to examine the bone and body composition effects of S-4, an aryl-propionamide derived Selective Androgen Receptor Modulator (SARM) in an ovariectomy induced model of accelerated bone loss. METHODS: One hundred twenty female Sprague-Dawley rats aged to twenty-three weeks were randomly assigned to twelve treatment groups. Drug treatment was initiated immediately following ovariectomy and continued for one hundred twenty days. Whole body bone mineral density (BMD), body composition, and lumbar vertebrae BMD were measured by dual energy x-ray absorptiometry. More stringent regional pQCT and biomechanical strength testing was performed on excised femurs. RESULTS: We found that S-4 treatment maintained whole body and trabecular BMD, cortical content, and increased bone strength while decreasing body fat in these animals. CONCLUSIONS: The data presented herein show the protective skeletal effects of S-4. Our previous reports have shown the tissue selectivity and muscle anabolic activity of S-4. Together these data suggest that S-4 could reduce the incidence of fracture via two different mechanisms (i.e., via direct effects in bone and reducing the incidence of falls through increased muscle strength). This approach to fracture reduction would be advantageous over current therapies in these patients which are primarily antiresorptive in nature.
Authors: Ramesh Narayanan; Matthew R Allen; Dana Gaddy; Susan A Bloomfield; Carolyn L Smith; Nancy L Weigel Journal: Bone Date: 2004-07 Impact factor: 4.398
Authors: Jeffrey D Kearbey; Wenqing Gao; Scott J Fisher; Di Wu; Duane D Miller; James T Dalton Journal: Pharm Res Date: 2009-09-01 Impact factor: 4.200
Authors: C Zhou; G Wu; Y Feng; Q Li; H Su; D E Mais; Y Zhu; N Li; Y Deng; D Yang; M-W Wang Journal: Br J Pharmacol Date: 2008-04-14 Impact factor: 8.739
Authors: Casey E Bohl; Zengru Wu; Jiyun Chen; Michael L Mohler; Jun Yang; Dong Jin Hwang; Suni Mustafa; Duane D Miller; Charles E Bell; James T Dalton Journal: Bioorg Med Chem Lett Date: 2008-09-05 Impact factor: 2.823
Authors: Kornelia J Skowron; Kenneth Booker; Changfeng Cheng; Simone Creed; Brian P David; Phillip R Lazzara; Amy Lian; Zamia Siddiqui; Thomas E Speltz; Terry W Moore Journal: Mol Cell Endocrinol Date: 2019-06-01 Impact factor: 4.102
Authors: Amanda Jones; Dong Jin Hwang; Charles B Duke; Yali He; Anjaiah Siddam; Duane D Miller; James T Dalton Journal: J Pharmacol Exp Ther Date: 2010-05-05 Impact factor: 4.030